BLACK DIAMOND THERAPEUTICS, INC. (BDTX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$12.06M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$11.26M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$10.98M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$13.42M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$12.06M | (m) | (m) | (m) | (m) | -$7.97M* | (m) | $7.39M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$11.26M | (m) | (m) | (m) | (m) | -$10.23M | (m) | $7.00M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$10.98M | (m) | (m) | (m) | (m) | -$7.85M* | (m) | $7.44M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$13.42M | (m) | (m) | (m) | (m) | -$9.16M* | (m) | $9.32M | (m) | $0.00* |
| 2025-03-31 | Reported | (m) | $54.53M | (m) | (m) | (m) | (m) | $53.41M | (m) | $10.51M | (m) | $226.00K |
| 2024-09-30 | Reported | (m) | -$18.13M | (m) | (m) | (m) | (m) | -$11.32M* | (m) | $12.91M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$22.13M | (m) | (m) | (m) | (m) | -$14.73M* | (m) | $12.56M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$20.25M | (m) | (m) | (m) | (m) | -$21.20M | (m) | $13.54M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$24.01M | (m) | (m) | (m) | $33.00K* | -$18.36M* | (m) | $16.15M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$20.03M | (m) | (m) | (m) | $0.00* | -$14.37M* | (m) | $13.15M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$21.56M | (m) | (m) | (m) | $0.00 | -$20.03M | (m) | $14.75M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$22.12M | (m) | (m) | (m) | -$8.00K* | -$16.48M* | (m) | $15.85M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$23.17M | (m) | (m) | (m) | $193.00K* | -$18.07M* | (m) | $16.20M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$25.68M | (m) | (m) | (m) | $7.00K | -$28.60M | (m) | $17.79M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$35.36M | (m) | (m) | (m) | $1.49M* | -$26.48M* | (m) | $27.63M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$34.72M | (m) | (m) | (m) | $848.00K* | -$25.16M* | (m) | $26.72M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$30.71M | (m) | (m) | (m) | $40.00K | -$24.45M | (m) | $22.82M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$23.18M | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$18.48M | (m) | $0.00 | (m) | $8.00K* | -$11.49M* | (m) | $12.93M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$15.03M | (m) | $0.00 | (m) | $25.00K* | -$13.57M* | (m) | $10.17M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$12.88M | (m) | $0.00 | (m) | $0.00 | -$11.32M | (m) | $7.35M | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$10.34M | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$8.15M | (m) | $0.00 | (m) | $11.00K* | -$5.31M* | (m) | $5.63M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$7.00M | (m) | $0.00 | (m) | -$2.00K* | -$5.00M* | (m) | $5.65M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$3.84M | (m) | $0.00 | (m) | $10.00K | -$6.88M | (m) | $3.01M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$3.05M | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$2.34M | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$1.91M | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$1.60M | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | $12.52M | (m) | (m) | (m) | (m) | $29.61M | (m) | $33.56M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$78.78M | (m) | (m) | (m) | $0.00 | -$62.30M | (m) | $51.31M | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$86.46M | (m) | (m) | (m) | $33.00K | -$66.72M | (m) | $59.35M | (m) | $0.00 |
| 2022-12-31 | Reported | (m) | -$92.83M | (m) | (m) | (m) | $192.00K | -$85.08M | (m) | $64.44M | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | -$126.87M | (m) | (m) | (m) | $2.71M | -$100.15M | (m) | $96.83M | (m) | $0.00 |
| 2021-09-30 | Rolling | (m) | -$123.97M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | Rolling | (m) | -$107.09M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | Rolling | (m) | -$87.40M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$69.57M | (m) | $0.00 | (m) | $142.00K | -$52.15M | (m) | $48.21M | (m) | $0.00 |
| 2020-12-31 | Rolling | (m) | -$69.57M* | (m) | $0.00* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | Rolling | (m) | -$56.73M* | (m) | $0.00* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | Rolling | (m) | -$46.40M* | (m) | $0.00* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | Rolling | (m) | -$38.37M* | (m) | $0.00* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$29.33M | (m) | $0.00 | (m) | $21.00K | -$24.67M | (m) | $21.75M | (m) | $0.00 |
| 2019-12-31 | Rolling | (m) | -$29.33M* | (m) | $0.00* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | Rolling | (m) | -$22.03M* | (m) | $0.00* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | Rolling | (m) | -$16.23M* | (m) | $0.00* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | Rolling | (m) | -$11.14M* | (m) | $0.00* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$8.90M | (m) | $0.00 | (m) | $76.00K | -$8.45M | (m) | $6.95M | (m) | $0.00 |
| 2018-12-31 | Rolling | (m) | -$8.90M* | (m) | $0.00* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |